Clinical trial NCT04839341: Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
Official title: A Phase I, Open-labeled Multicenter Study to Determine Pharmacokinetics, Safety, Tolerability and Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Relapsed/Refractory AML
Keywords: AML
Lead sponsor: Apollomics Inc.
Sponsor class: INDUSTRY
Collaborators: name: Zhejiang CrownMab Biotech Co. Ltd
First posted: 2021-04-09
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.

Detailed description: This study is a multicenter open-labelled study conducted in subjects with relapsed or refractory AML in China. The study includes the following phases: screening phase, induction phase, consolidation phase baseline, consolidation phase and follow-up period.

Screening phase:

This study will enroll 12 subjects, who are 18 to 60 years (inclusive) at the time of signing the Informed Consent Form (ICF), and with the diagnosis as relapsed or refractory AML. Screening is conducted 21 days to 2 days before administration, and signed ICF by the subject must be obtained before screening.

Baseline period:

The baseline period is 1 day before study drug administration.

Induction treatment:

During the induction phase, subjects will receive 8 consecutive days of uproleselan treatment and 5 consecutive days of MEC (mitoxantrone, etoposide, and cytarabine combined regimen) chemotherapy.

Consolidation baseline:

The baseline of the consolidation phase is 1 day before the treatment administration of the consolidation phase.

Consolidation treatment:

Subjects who met the criteria for consolidation treatment started the consolidation period at the 29th day of the previous treatment cycle at the earliest and the 65th day at the latest.

Follow-up period:

Each subject should complete the following follow-up stage: (1) Response evaluation to determine remission to the induction treatment (induction period); (2) EOT assessment after completing the last consolidation treatment cycle; (3) Death. Survival and long-term follow-up, including initiation of new anti-leukemia treatment (within 6 months after the last uproleselan/placebo administration), recurrence, HSCT and survival events, monthly (±14 days) for 2 years after the end of treatment, and afterwards quarterly (±14 days). The longest survival follow-up time is 3 years (calculated from the start of treatment).

Eligibility criteria: Inclusion Key Criteria:

1. ≥18 years and ≤60 years in age
2. AML (including secondary AML) diagnosed as per WHO standards (2008).
3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug \[HMA\] can be used before and after chemotherapy.

   1. For relapse AML, it must be the first or second relapse, and remain untreated.
   2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed.
4. ECOG performance status score is 0 to 2.
5. Stable hemodynamics and good organ function and good organ function.

Exclusion key Criteria:

1. Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.
2. Active signs or symptoms of CNS involvement by malignancy.
3. Stem cell transplantation ≤4 months prior to dosing.
4. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.
5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
6. Inadequate organ function.
7. Abnormal liver function.
8. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
9. Moderate kidney dysfunction (glomerular filtration rate \<45 mL/min).
10. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
11. Clinically significant cardiovascular disease.
12. Major surgery within 4 weeks of dosing.

Primary outcomes:
measure: Peak plasma concentration (Tmax)
timeFrame: 14 days
measure: Peak plasma concentration (Cmax)
timeFrame: 14 days
measure: Area under the plasma concentration-time curve from time zero to 12 hours (AUC0-12)
timeFrame: 14 days
measure: The area under the plasma concentration-time curve (AUC0-t) from time zero to the last measurable time point
timeFrame: 14 days
measure: The Incidence of Adverse Events
timeFrame: Up to 10 months
measure: The tolerance of participants with relapsed/refractory AML.
timeFrame: Up to 10 months
Secondary outcomes:
measure: OS
timeFrame: Up to 3 years
measure: Remission rate (rate of CR, CR/CRi and CR/CRh)
timeFrame: Up to 60 days
measure: CTCAE grade 3 and 4 oral mucositis
timeFrame: Up to 254 days
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
state: Tianjin
city: Hangzhou
country: China
facility: The First Affiliated Hospital of Zhejiang University
Study officials:
affiliation: Investigator
name: Jianxiang Wang, Phd
role: PRINCIPAL_INVESTIGATOR
References: